EI
LGND icon

EAM Investors’s Ligand Pharmaceuticals LGND Stock Holding History

EAM Investors’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-21,092
Closed -$3.99M – 336
2025
Q4 		$3.99M Sell
21,092
-9,083
-30% -$1.75M 0.44% 117
2025
Q3 		$5.26M Buy
+30,175
New +$4.49M 0.6% 51
2018
Q4 		– Sell
-22,442
Closed -$3.84M – 285
2018
Q3 		$3.84M Sell
22,442
-1,709
-7% -$258K 0.57% 38
2018
Q2 		$3.12M Sell
24,151
-9,539
-28% -$1.06M 0.49% 82
2018
Q1 		$3.47M Buy
+33,690
New +$3.33M 0.58% 43
2015
Q4 		– Sell
-35,426
Closed -$1.89M – 339
2015
Q3 		$1.89M Sell
35,426
-8,233
-19% -$500K 0.3% 154
2015
Q2 		$2.75M Sell
43,659
-29,064
-40% -$1.59M 0.32% 148
2015
Q1 		$3.5M Buy
+72,723
New +$2.79M 0.4% 79
2014
Q3 		– Sell
-27,674
Closed -$1.07M – 338
2014
Q2 		$1.07M Sell
27,674
-13,449
-33% -$546K 0.2% 282
2014
Q1 		$1.73M Sell
41,123
-5,944
-13% -$248K 0.31% 118
2013
Q4 		$1.54M Sell
47,067
-56
-0.1% -$1.82K 0.28% 138
2013
Q3 		$1.27M Sell
47,123
-79,980
-63% -$2.25M 0.25% 156
2013
Q2 		$2.97M Buy
+127,103
New +$2.29M 0.64% 21

Other funds holding LGND

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
CC
Chicago Capital Chicago, Illinois $3.71B AUM 19.51% 1-Year Est. Return

EAM Investors's LGND Position: Q1 2026 in Review

EAM Investors sold out of Ligand Pharmaceuticals (LGND) in Q1 2026, closing a stake of 21,092 shares — an estimated $3.99M sold.

EAM Investors first reported a position in LGND in Q2 2013 and held it in 13 quarters. The position peaked at $5.26M in Q3 2025. 357 funds tracked by Wall St. Rank hold LGND as of Q1 2026.

  • EAM Investors reported no remaining Ligand Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • EAM Investors sold 21,092 Ligand Pharmaceuticals shares in Q1 2026, an estimated $3.99M.
  • EAM Investors first reported a position in Ligand Pharmaceuticals in Q2 2013 and held it in 13 quarters.
  • EAM Investors's Ligand Pharmaceuticals position peaked at $5.26M in Q3 2025.
  • 357 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q1 2026.

Based on EAM Investors's 13F filing for Q1 2026, filed 13 May 2026.